Philips' Respironics unit appoints new chief technology officer
This article was originally published in Clinica
Executive Summary
John Pritchard has joined Philips' Respironics drug delivery unit as chief technology officer. In his new role, Dr Pritchard will be responsible for global R&D activities in respiratory drug delivery, focusing on next-generation adaptive aerosol delivery technology. These devices are designed to only deliver medication when the patient breathes in, increasing the chance of it reaching deep inside the lung and reducing the amount of escaped medication. Dr Pritchard has over 30 years of experience in the aerosol and respiratory field, most recently at AstraZeneca as head of respiratory project management. He has also worked for 3M Healthcare and GlaxoSmithKline. Dr Pritchard replaces John Denyer, who is retiring, having worked for Respironics since 1988.